medigraphic.com
Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán

2011, Number 6

<< Back Next >>

Rev Invest Clin 2011; 63 (6)

Association between neuropathy and peripheral vascular insufficiency in patients with diabetes mellitus type 2

Millán-Guerrero RO, Vásquez C, Isaís-Millán S, Trujillo-Hernández B, Caballero-Hoyos R

Language: Spanish
References: 37
Page: 621-629
PDF size: 203.10 Kb.


ABSTRACT

Introduction. Diabetes mellitus (DM) can present complications of neuropathy and peripheral arterial disease with high risk for developing foot ulcers and consequent amputations. Objective. To identify the association between peripheral vascular disease, and neuropathy in type 2 Diabetes mellitus patients from the Hospital General de Zona No. 1 IMSS in Colima, Mexico. Material and methods. Cross-sectional study of 80 patients with diabetes mellitus evaluated by means of the Edinburgh Claudication Questionnaire, Michigan Neuropathy Screening Instrument, ankle-arm index, Motor Nerve Conduction Velocity, and H-reflex. Results. 51 women and 29 men were studied. Mean age was 53.9 ± 9.6 years, mean diabetes mellitus progression was 8 ± 6.6 years and mean glucose level was 283 ± 110 mg/mL. Neuropathy presented in 65 patients (81.2%). Ankle/arm index revealed 19% of patients presented with moderate peripheral vascular insufficiency. Motor Nerve Conduction Velocity was abnormal in 40% of patients and H-reflex was absent in 70%. Discussion. Grade 2 motor-sensitive polyneuropathy was found in 70-80% of patients and moderate peripheral vascular insufficiency in 19%. It can thus be inferred that the complication of diabetic neuropathy appears before that of peripheral vessel damage.


REFERENCES

  1. Arun V, Krishnan M, Ciernan C. Altered nerve excitability properties in established diabetic neuropathy. Brain 2005; 128: 1178-87.

  2. DCCT Research Group. Factors in development of diabetic neuropathy. Baseline analysis of neuropathy in feasibility phase of Diabetes Control and Complications Trial (DCCT). Diabetes 1988; 37: 476-81.

  3. Pirart J. Diabetes mellitus and its degenerative complications: a prospective study of 4400 patient observed between 1947 and 1973. Diabetes Care 1978; 1: 168.

  4. Bloomgarden ZT. Diabetic neuropathy. Diabetes Care 2008; 31: 616-21.

  5. Dyck PJ. Detection, characterization, and staging of polyneuropathy: assessed in diabetics. Muscle Nerve 1988; 11: 21-32.

  6. Argoff CE, Cole BE, Fishbain DA, Irving GA. Diabetic peripheral neuropathic pain: clinical and quality-of-life issues. Mayo Clin Proc 2006; 81: 4(Suppl.): S3-S11.

  7. England JD, Gronseth GS, Franklin G, Carter GT, Kinsella LJ, et al. Practice parameter: evaluation of distal symmetric polyneuropathy. Role of autonomic testing, nerve biopsy, and skin biopsy (an evidence-based review). Neurology 2009; 72: 177-84.

  8. Hoffmann P. Über die Beziehungen der Sehnenreflexe zur willkürlichen Bewegung und zum Tonus. Z Biol 1918; 68: 351-70.

  9. American Diabetes Association. Position statement. Standards of medical care in diabetes-2008. Diabetes Care 2008; 31: S12-S54.

  10. Reiber GE. Epidemiology of foot ulcers and amputation in the diabetic foot. In: Bowker JH, Pfeifer MA (eds.). The diabetic foot. 6th. Ed. St. Louis (MO): Mosby; 2001, p. 13-32.

  11. Murabito JM, Evans JC, Nieto K, et al. Prevalence and clinical correlates of peripheral arterial disease in the Framingham Offspring Study. Am Heart J 2002; 143: 961-5.

  12. Hackam DG, Goodman SG, Anand SS. Management of risk in peripheral artery disease: Recent therapeutic advances. Am Heart J 2005; 150: 35-40.

  13. Criqui MH, Denenber JO, Langer RD, et al. The epidemiology of peripheral arterial disease: importance of identifying the population at risk. Vasc Med 1997; 2: 221-6.

  14. Hirsch AT, Criqui MH, Treat-Jacobson D, et al. Peripheral arterial disease detection, awareness, and treatment in primary care. JAMA 2001; 286: 1317.

  15. Wolff TA, Gutke GD, CAPT. Screening for Peripheral Arterial Disease. Am Fam Physician 2006; 74: 636.

  16. Burns TM, Mauermann ML. The evaluation of polyneuropathies. Neurol Clin Pract 2011; 76(Suppl. 2): S6-S13.

  17. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2008; 31(S1): S55-S60.

  18. American Diabetes Association. Standards of medical care in diabetes (position statement). Diabetes Care 2005; 28(Suppl.): S4-S36.

  19. Leng GC, Fowkes FG. The Edinburgh Claudication Questionnaire: an improved version of the WHO/Rose Questionnaire for use in epidemiological surveys. J Clin Epidemiol 1992; 45: 1101-9.

  20. Collins TC, Suarez-Almazor M, Petersen NJ, O’Malley KJ. A Spanish translation of the Walking Impairment Questionnaire was validated for patients with peripheral arterial disease. J Clin Epidemiol 2004; 57: 1305-15.

  21. Makdisse M, Neto RN, Chagas ACP, Brasil D, Borges JL, et al. Cross-Cultural Adaptation and Validation of the Brazilian Portuguese Version of the Edinburgh Claudication Questionnaire. Arq Bras Cardiol 2007; 88: 441-5.

  22. Grenon SM, Gagnon J, Hsiang Y. Ankle-Brachial Index for assessment of peripheral arterial disease. N Engl J Med 2009; 361: e40.

  23. Bernstein EF, Fronek A. Current statues of non-invasive tests in the diagnosis of peripheral arterial disease. Surg Clin North Am 1982; 62: 473-487.

  24. The Diabetes Control and Complications Trial Investigators. Effect of intensive diabetes management on macrovascular events and risk factors in the Diabetes Control and Complications Trial. Am J Cardiol 1995; 75: 894-903.

  25. Bax G, Fagherazzi C, Piarulli F, Nicolucci A, Fedele D. Reproducibility of Michigan Neuropathy Screening Instrument (MNSI). A comparison with tests using the vibratory and thermal perception thresholds. Diabetes Care 1996; 19: 904-5.

  26. Moghtaderi A, Bakhshipour A, Rashidi H, Validation of Michigan neuropathy screening instrument for diabetic peripheral neuropathy. Clin Neurol Neurosurg 2006; 108: 477-81.

  27. American Diabetes Association, American Academy of Neurology. Report and re commendations of the San Antonio Conference on Diabetic Neuropa thy. Diabetes Care 1988; 11: 592-7.

  28. Freund FG, Martin WE, Hornbein TF. The H-reflex as a measure of anesthetic potency in man. Anesthesiology 1969; 30: 642-7.

  29. Zhou HH, Jin TT, Qin B, Turndorf H. Suppression of spinal cord motoneuron excitability correlates with surgical immobility during isoflurane anesthesia. Anesthesiology 1998; 88: 955-61.

  30. Strakowski JA, Redd DD, Johnson EW, Pease WS. H reflex and F wave latencies to soleus normal values and side-to-side differences. Am J Phys Med Rehabil 2001; 80: 491-3.

  31. Lachman T, Shahani BT, Young RR. Late responses as aides to diagnosis of peripheral neuropathies. J Neurol Neurosurg Psychiatry 1980; 43: 156-62.

  32. Hulley SB, Gove S, Cummings SR. Elección de los individuos que participarán en el estudio: especificación y muestreo. En: Hulley SB, Cummings SR (eds.). Diseño de la Investigación Clínica. España: Harcourt Brace; 1997, p. 21-55.

  33. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. The Lancet 1986; 327: 307-10.

  34. Monge-Argilés JA, Fríes-Ramos A, Martí-Martínez S, Leiva-Santana C. Experiencia de dos años en una consulta específica de sistema nervioso autónomo. Rev Neurol 2009; 48: 566-71.

  35. Otero-Siliceo E, Ruano-Calderón LA. Neuropatía diabética: ¿una enfermedad vascular? Rev Neurol 2003; 37: 658-61.

  36. Boulton AJM, Kirsner RS, Vileikyte L. Neuropathic foot ulcers. N Engl J Med 2004; 351: 48-55.

  37. Malone JM, Snyder M, Anderson G, et al. Prevention of amputation by diabetic education. Am J Surg 1989; 58: 520-3.




2020     |     www.medigraphic.com